Literature DB >> 2462591

Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma.

F Momburg1, A Ziegler, J Harpprecht, P Möller, G Moldenhauer, G J Hämmerling.   

Abstract

A panel of colorectal carcinomas has been examined immunohistologically with mAb specific for allodeterminants of HLA-A or HLA-B, and with mAb reactive with HLA-A,B,C framework determinants or beta 2-microglobulin. Out of 85 carcinomas, 5 cases were completely negative for all class I Ag in the tumor cell population. Fifteen cases exhibited a differential expression of HLA-A and HLA-B products in all tumor cells or in a subset. Such tumor cells showed strong staining with monomorphic HLA antibodies but failed to stain with certain allospecific mAb. Negativity of tumor cells was scored only when normal stromal cells within the tumor mass were clearly labeled, indicating expression of the particular allodeterminant(s) in the given tissue. Four carcinomas showed a selective loss of HLA-A2 or a non-A2 HLA-A allospecificity in all tumor cells or a major subset, whereas HLA-B Ag were expressed. Seven cases showed a selective loss of the HLA-Bw6 superspecificity in the tumor cell population; HLA-Bw4 and HLA-A Ag were present. Three cases exhibited a combined loss of HLA-A2 and HLA-Bw6 Ag, with non-A2 HLA-A and HLA-Bw4 Ag being expressed. A further case was HLA-Bw6/Bw4 negative in a major tumor cell subset and HLA-A negative in the complementary minor subset. The results show that a considerable proportion of colorectal carcinomas is heterogeneous with regard to HLA-A and HLA-B expression. The reasons for the appearance of tumor subsets with complete loss of class I Ag or selective loss of only HLA-A or HLA-B Ag are not clear, but it is conceivable that some of them arose because they have escaped immunoselection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2462591

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  An HLA-B regulatory element binds a factor immunologically related to the upstream stimulation factor.

Authors:  J Girdlestone
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

Review 2.  The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

Authors:  Arfon G M T Powell; Paul G Horgan; Joanne Edwards
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

3.  Sequence polymorphism in the HLA-B promoter region.

Authors:  Z Yao; A Volgger; S Scholz; E D Albert
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

4.  Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia.

Authors:  M E Smith; S G Marsh; J G Bodmer; K Gelsthorpe; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

6.  Immunotherapy of human colon cancer by antibody-targeted superantigens.

Authors:  M Dohlsten; P A Lando; P Björk; L Abrahmsén; L Ohlsson; P Lind; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

7.  The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer.

Authors:  Craig Blum; Amanda Graham; Matt Yousefzadeh; Jessica Shrout; Katie Benjamin; Murli Krishna; Raza Hoda; Rana Hoda; David J Cole; Elizabeth Garrett-Mayer; Carolyn Reed; Michael Wallace; Michael Mitas
Journal:  Int J Oncol       Date:  2008-09       Impact factor: 5.650

8.  Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Authors:  F M Marincola; P Shamamian; T B Simonis; A Abati; J Hackett; T O'Dea; P Fetsch; J Yannelli; N P Restifo; J J Mulé
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-07

9.  Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer.

Authors:  L Kaklamanis; A Townsend; I A Doussis-Anagnostopoulou; N Mortensen; A L Harris; K C Gatter
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

10.  Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area.

Authors:  B Ostenstad; T Lea; E Schlichting; M Harboe
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.